- –World market, 2023
- –Projected, 2033
- –Growth a year (CAGR)
- –Active clinical trials worldwide
Alexipharmic Drugs by country and region
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
Philippines
Russia
Saudi Arabia
Singapore
South Africa
Spain
Thailand
UAE
UK
US"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 15,648 papers since 2021
- Extracorporeal treatment in lithium poisoning: Aligning treatment timing with neurological outcomes. British journal of clinical pharmacology, 2026
- A ruthenium-coordinated sodium alginate hydrogel-based electroluminescent sensor for highly sensitive analysis of Paraquat. Talanta, 2026
- Remove the Metal Bullet Fragment Retained in the Cranio-Maxillofacial Region Using a Dynamic Navigation System. The Journal of craniofacial surgery, 2025
- A Poisoning Outbreak Caused by Paralytic Shellfish Toxins in the Absence of Visible Red Tides - Zhanjiang City, Guangdong Province, China, February 2026. China CDC weekly, 2026
- Avermectin poisoning with panic-like symptoms: a case series. Frontiers in toxicology, 2026
Key companies in Alexipharmic Drugs
AstraZeneca
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Mylan N.V.
Novartis AG
Sanofi S.A.
Quick answers
How much research is published on Alexipharmic Drugs?
PubMed lists about 15,648 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.